Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Type
News Topics
- (-) Biomedical (2)
- (-) Fusion (2)
- (-) Physics (1)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (4)
- Bioenergy (1)
- Computer Science (1)
- Decarbonization (1)
- Isotopes (3)
- Molten Salt (3)
- Neutron Science (2)
- Nuclear Energy (11)
- Space Exploration (1)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
Juergen Rapp, a distinguished R&D staff scientist in ORNL’s Fusion Energy Division in the Nuclear Science and Engineering Directorate, has been named a fellow of the American Nuclear Society
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.